Sep 17, 2019
Allergan Announces Commencement of Mailing of Proxy Statement
Sep 10, 2019
Allergan Shareholder Meetings Scheduled for October 14, 2019
Sep 03, 2019
Allergan Receives FDA Approval of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula
Aug 06, 2019
Burns Charest LLP Joins Legal Team in High-Profile Pharmaceutical Patent Fraud Cases
Aug 06, 2019
Allergan Reports Second Quarter 2019 Financial Results
Aug 02, 2019
Allergan to Report Second Quarter 2019 Financial Results
Jul 29, 2019
Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign
Jul 24, 2019
Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
Jul 19, 2019
Allergan Declares Third Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share
Jul 18, 2019
Amgen And Allergan's MVASI(TM) (bevacizumab-awwb) And KANJINTI(TM) (trastuzumab-anns) Now Available In The United States
Jul 09, 2019
Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting
Jun 24, 2019
Allergan Receives FDA Clearance For CoolTone(TM) Device
Jun 21, 2019
FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
Jun 13, 2019
FDA Approves Amgen And Allergan's KANJINTI(TM) (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
May 28, 2019
Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression
May 24, 2019
Allergan Announces Updated Presentation Time at the Bernstein Strategic Decisions Conference
May 23, 2019
Allergan to Present at the Jefferies 2019 Healthcare Conference
May 17, 2019
Allergan Expands PLEDGE Clinical Research Program in Diabetic Gastroparesis
May 16, 2019
Allergan to Present at the Bernstein Strategic Decisions Conference
May 15, 2019
Allergan to Present VRAYLAR® (cariprazine) Data at the American Psychiatric Association (APA) 2019 Annual Meeting Highlighting Continued Commitment to Mental Health